Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 59, 331-335, January 1, 1999]
© 1999 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, A. M. R.
Right arrow Articles by Gomer, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, A. M. R.
Right arrow Articles by Gomer, C. J.
[Cancer Research 59, 331-335, January 15, 1999]
© 1999 American Association for Cancer Research


Advances in Brief

Photodynamic Therapy Sensitivity Is Not Altered in Human Tumor Cells after Abrogation of p53 Function1

Anita M. R. Fisher, Angela Ferrario, Natalie Rucker, Sha Zhang and Charles J. Gomer2

Clayton Ocular Oncology Center, Children’s Hospital Los Angeles [A. M. R. F., A. F., N. R., C. J. G.], and Departments of Pediatrics [C. J. G.], Radiation Oncology [C. J. G.], and Molecular Pharmacology and Toxicology [C. J. G., S. Z.], University of Southern California, Los Angeles, California 90027

Photodynamic therapy (PDT) is an effective local cancer treatment that induces cytotoxicity through the intracellular generation of reactive oxygen species. The current study investigated whether abrogation of wild-type p53 expression modified the sensitivity of tumor cells to PDT-mediated oxidative stress. In these experiments, human colon (LS513) and breast (MCF-7) carcinoma cells exhibiting a wild-type p53 phenotype were directly compared to LS513 and MCF-7 cells with abrogated p53 function induced by stable integration of the human papillomavirus type 16 E6 viral oncoprotein. The effectiveness of this viral oncoprotein to target p53 for degradation was confirmed using a p53 transactivation reporter gene assay. Western analysis also confirmed attenuated expression of p53 in E6-transfected cells. Photosensitivity of PDT-treated cells was measured by a clonogenic assay and found to be equivalent for parental and p53-abrogated cells. PDT-mediated oxidative stress resulted in a rapid shift of pRb from a hyperphosphorylated form to a predominantly underphosphorylated form in parental cells that was not preceded by increases in p53 or p21 expression. Hypophosphorylated pRb was also observed in PDT-treated LS513/E6 and MCF-7/E6 cells, further indicating that p53 was not involved in this process. Delayed expression of p53 and p21 proteins was seen in parental cells 24–48 h after photosensitization. Cell cycle analysis showed that the abrogation of p53 had minimal effects on an observed PDT-induced G1 block. Rapid induction of apoptosis was documented in PDT-treated LS513 cells, whereas LS513/E6 treated cells exhibited reduced apoptosis in response to PDT. The MCF-7 cell lines exhibited a minimal apoptotic response to PDT. These results indicate that p53 expression does not directly modulate tumor cell sensitivity to PDT in either apoptosis-responsive (LS513) or nonresponsive (MCF-7) cells.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
E. Crescenzi, A. Chiaviello, G. Canti, E. Reddi, B. M. Veneziani, and G. Palumbo
Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299).
Mol. Cancer Ther., March 1, 2006; 5(3): 776 - 785.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Crescenzi, L. Varriale, M. Iovino, A. Chiaviello, B. M. Veneziani, and G. Palumbo
Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells
Mol. Cancer Ther., May 1, 2004; 3(5): 537 - 544.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Ferrario, K. F. von Tiehl, N. Rucker, M. A. Schwarz, P. S. Gill, and C. J. Gomer
Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma
Cancer Res., August 1, 2000; 60(15): 4066 - 4069.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
C. M. Whitacre, D. K. Feyes, T. Satoh, J. Grossmann, J. W. Mulvihill, H. Mukhtar, and N. L. Oleinick
Photodynamic Therapy with the Phthalocyanine Photosensitizer Pc 4 of SW480 Human Colon Cancer Xenografts in Athymic Mice
Clin. Cancer Res., May 1, 2000; 6(5): 2021 - 2027.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. C. Luna, A. Ferrario, S. Wong, A. M. R. Fisher, and C. J. Gomer
Photodynamic Therapy-mediated Oxidative Stress as a Molecular Switch for the Temporal Expression of Genes Ligated to the Human Heat Shock Promoter
Cancer Res., March 1, 2000; 60(6): 1637 - 1644.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.